Materias dentro de su búsqueda.
Materias dentro de su búsqueda.
-
21por Berrim, K., Lakhoua, G., Daly, W., Zaiem, A., Kastalli, S., Daghfous, R., El Aidli, S.“…OBJECTIF: Herein, we report an original clinical observation of EN occurring after the first dose of AstraZeneca COVID-19 vaccine (vaxzevria), a viral vector vaccine, without recurrence after the second dose. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
22
-
23por Østergaard, Søren Dinesen, Schmidt, Morten, Horváth-Puhó, Erzsébet, Thomsen, Reimar Wernich, Sørensen, Henrik ToftEnlace del recurso
Publicado 2021
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
24
-
25
-
26por Manus, Jean-MarieEnlace del recurso
Publicado 2021
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
27
-
28
-
29
-
30“…OBJECTIVES: The objective of this study was to analyse the media discourse about the AstraZeneca COVID-19 vaccine on Twitter. STUDY DESIGN: The study design used in this study is data scraping, media analysis, social network analysis, and botometer. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
31
-
32por Cross, Samuel, Rho, Yeanuk, Reddy, Henna, Pepperrell, Toby, Rodgers, Florence, Osborne, Rhiannon, Eni-Olotu, Ayolola, Banerjee, Rishi, Wimmer, Sabrina, Keestra, Sarai“…OBJECTIVES: The Oxford–AstraZeneca COVID-19 vaccine (ChAdOx1 nCoV-19, Vaxzevira or Covishield) builds on two decades of research and development (R&D) into chimpanzee adenovirus-vectored vaccine (ChAdOx) technology at the University of Oxford. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
33por Alhammad, Norah S, Milibary, Heba H, Baghdadi, Razan R, Alawadi, Toleen M, Hudairy, Rawan E“…In this article, we report on the clinical and histopathological features of generalized pruritic morbilliform eruption in a 28-year-old female following her second dose of Oxford/AstraZeneca COVID-19 vaccine. The reaction started 12 hours after receiving the vaccine with no other identifiable cause. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
34por González-Romero, N., Morillo Montañes, V., Vicente Sánchez, I., García García, M.Enlace del recurso
Publicado 2022
Enlace del recurso
Online Artículo Texto -
35“…We report a case of exfoliative bullous rash in a 69-year-old lady admitted to the acute medicine unit with complaints of rash post-AstraZeneca (AZ) vaccine administration. The rash initially started under her breast and had spread to other parts of the body without mucosal involvement. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
36
-
37por Letafati, Arash, Eyvazzadeh, Nooshin, Gharehkhani, Amirhossein, Khorshidian, Ayeh, Chalabiani, Siavash, Soufiani, Elnaz Khodadoust, Khakpoor, Niloofar, Shamsodini, Benyamin, Beheshti, Taranom, Bavili Olyaei, Raha Taheri, Soleimani, Anahita, Melyani, Fatemeh, Hossein, Ghazal Mashhadi“…RESULTS: Out of 346 cases with respiratory symptoms, 120 cases tested positive for SARS-CoV-2 and had received two doses of Sinopharm and a different booster dose of either AZD1222 (AstraZeneca) or BIBP (Sinopharm). Among these 120 patients, vaccination with AZD1222 as a booster dose resulted in fewer symptoms compared to those vaccinated with three doses of BIBP. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
38“…We report a case of a patient who experienced a rare occurrence of reactive arthritis in the right knee joint that manifested insidiously as pain, heat, and swelling on the second day following vaccination with the Oxford-AstraZeneca COVID-19 vaccine. The patient underwent a series of investigations, confirming the suspected diagnosis and ruling out other possible diseases. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
39por Katsouli, Olga K., Lainis, Vasileios G., Kapellos, Gerasimos G., Vlachoyiannopoulos, Panayiotis G.“…We report a case of a 52-year-old female with Large Vessel Vasculitis (LVV) after vaccination with Oxford-AstraZeneca COVID-19 vaccine. She was presented with fever, started two weeks after the second dose of vaccine. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
40por Manus, Jean-MarieEnlace del recurso
Publicado 2021
Enlace del recurso
Enlace del recurso
Online Artículo Texto